Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio is poised to successfully launch their lead candidate in Stargardt disease (STGD1) - the first ever treatment for this rare, debilitating condition. With a target action date of February 2027, a successful launch would address a significant unmet medical need for ~53k US STGD1 patients and potentially generate ~$5B in peak US sales, while the recent submission of a New Drug Application in Japan provides additional upside potential. Additionally, Belite's strong financial position, with cash and investments totaling $780.0M, mitigates risks related to financing and cash burn.

Bears say

Belite Bio is a clinical-stage biopharmaceutical company with a negative outlook due to various risks including financing risk, clinical risk, and the possibility of facing challenges in gaining market share in a competitive market for its lead drug, tinlarebant, which is being developed for the treatment of degenerative retinal diseases such as GA and STGD1. Despite strong price performance, there are uncertainties surrounding the launch execution and market access efforts for this drug. Additionally, the company's success is dependent on its ability to secure sufficient funding and the safety and efficacy of its products in clinical trials.

BLTE has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Strong Buy based on their latest research and market trends.

According to 7 analysts, BLTE has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $226.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $226.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.